JPMorgan raised the firm’s price target on BeOne Medicines (ONC) to $345 from $321 and keeps an Overweight rating on the shares. The firm removed previously assumed Inflation Reduction Act price negotiation for Brukinsa following the One Big Beautiful Bill passage. The analyst believes Brukinsa is now exempt from IRA price negotiations as the bill exempts drugs from negotiation that have more than one orphan indication.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines price target raised to $349 from $311 at RBC Capital
- BeOne announces EC approval of Tevimbra in combination with chemotherapy
- Buy Rating for BeOne Medicines: Promising Developments and Strategic Positioning
- Beigene’s BG-68501 Study: A Potential Game-Changer in Oncology
- Jazz Pharmaceuticals and BeiGene’s Promising Phase 3 Study for Advanced Gastric and Esophageal Cancers